Novocure Ltd
NVCR12.040USD
-0.500-3.99%
收盘 07/25, 16:00（美东）报价延迟15分钟
1.35B总市值
亏损市盈率 TTM
关于 Novocure Ltd 公司
NovoCure Limited 是一家全球性肿瘤学公司。该公司从事肿瘤治疗场 (TTFields) 设备的开发、制造和商业化，包括用于治疗实体肿瘤癌症的 Optune 和 Optune Lua。其商业化产品在某些国家已获准用于治疗患有胶质母细胞瘤、恶性胸膜间皮瘤和胸膜间皮瘤的成年患者。该公司正在进行关键研究，评估 TTFields 在治疗卵巢癌、非小细胞肺癌 (NSCLC) 脑转移（脑转移）和胰腺癌中的应用。其主要优先事项是推动其商业 TTFields 设备 Optune 的商业化应用。该公司还拥有在中国、香港、澳门和台湾销售 Optune 的许可。该公司正在进行或已完成临床试验，研究肿瘤治疗场在脑转移、胃癌、胶质母细胞瘤、肝癌、非小细胞肺癌、胰腺癌和卵巢癌中的应用。
公司简介
公司代码NVCR
公司名称Novocure Ltd
上市日期Oct 01, 2015
成立日期2000
CEOMs. Ashley Cordova
员工数量1488
证券类型Ordinary Share
年结日Oct 01
公司地址No. 4 The Forum
城市SAINT HELIER
上市交易所NASDAQ Global Select Consolidated
国家Jersey
邮编JE2 4UF
电话441534756700
网址https://www.novocure.com/
公司代码NVCR
上市日期Oct 01, 2015
成立日期2000
公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Asaf Danziger
Mr. Asaf Danziger
Director
Director
416.47K
+0.20%
Mr. William F. (Bill) Doyle
Mr. William F. (Bill) Doyle
Executive Chairman of the Board
Executive Chairman of the Board
413.01K
--
Ms. Ashley Cordova
Ms. Ashley Cordova
Chief Executive Officer, Director
Chief Executive Officer, Director
357.31K
+0.23%
Dr. Uri Weinberg, M.D., Ph.D.
Dr. Uri Weinberg, M.D., Ph.D.
Chief Innovation Officer
Chief Innovation Officer
221.22K
+16.80%
Mr. Mukund Paravasthu
Mr. Mukund Paravasthu
Chief Operating Officer
Chief Operating Officer
83.56K
-0.70%
Mr. Christoph Brackmann
Mr. Christoph Brackmann
Chief Financial Officer
Chief Financial Officer
66.17K
+490.85%
Dr. David T. Hung, M.D.
Dr. David T. Hung, M.D.
Independent Director
Independent Director
23.41K
+77.43%
Mr. Martin J. Madden
Mr. Martin J. Madden
Independent Director
Independent Director
18.67K
-5.08%
Ms. Kristin Stafford
Ms. Kristin Stafford
Independent Director
Independent Director
14.27K
+252.06%
Dr. Allyson Ocean, M.D.
Dr. Allyson Ocean, M.D.
Independent Director
Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Asaf Danziger
Mr. Asaf Danziger
Director
Director
416.47K
+0.20%
Mr. William F. (Bill) Doyle
Mr. William F. (Bill) Doyle
Executive Chairman of the Board
Executive Chairman of the Board
413.01K
--
Ms. Ashley Cordova
Ms. Ashley Cordova
Chief Executive Officer, Director
Chief Executive Officer, Director
357.31K
+0.23%
Dr. Uri Weinberg, M.D., Ph.D.
Dr. Uri Weinberg, M.D., Ph.D.
Chief Innovation Officer
Chief Innovation Officer
221.22K
+16.80%
Mr. Mukund Paravasthu
Mr. Mukund Paravasthu
Chief Operating Officer
Chief Operating Officer
83.56K
-0.70%
Mr. Christoph Brackmann
Mr. Christoph Brackmann
Chief Financial Officer
Chief Financial Officer
66.17K
+490.85%
收入明细
单位: USD更新时间: 7月6日 周日
单位: USD更新时间: 7月6日 周日
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
暂无数据
地区USD
名称
营收
占比
United States
93.15M
60.10%
Germany
18.72M
12.08%
France
17.86M
11.52%
Other EMEA countries
11.94M
7.70%
Japan
8.71M
5.62%
Greater China
4.62M
2.98%
业务
地区
暂无数据
股东统计
更新时间: 7月23日 周三
更新时间: 7月23日 周三
持股股东
股东类型
持股股东
持股股东
占比
Fidelity Management & Research Company LLC
14.75%
The Vanguard Group, Inc.
10.04%
BlackRock Institutional Trust Company, N.A.
7.86%
Wyss (Hansjorg)
7.28%
Soleus Capital Management, L.P.
4.94%
Other
55.13%
持股股东
持股股东
占比
Fidelity Management & Research Company LLC
14.75%
The Vanguard Group, Inc.
10.04%
BlackRock Institutional Trust Company, N.A.
7.86%
Wyss (Hansjorg)
7.28%
Soleus Capital Management, L.P.
4.94%
Other
55.13%
股东类型
持股股东
占比
Investment Advisor
48.81%
Investment Advisor/Hedge Fund
14.72%
Hedge Fund
12.72%
Individual Investor
10.05%
Research Firm
1.57%
Sovereign Wealth Fund
0.87%
Pension Fund
0.42%
Bank and Trust
0.32%
Venture Capital
0.12%
Other
10.39%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
675
112.27M
100.70%
-3.75M
2025Q1
737
108.90M
97.99%
+1.47M
2024Q4
761
104.07M
94.71%
-2.49M
2024Q3
766
105.53M
97.47%
-2.32M
2024Q2
782
105.08M
97.13%
+3.28M
2024Q1
775
93.94M
87.31%
-7.19M
2023Q4
784
94.40M
88.34%
-2.12M
2023Q3
811
96.26M
90.17%
-961.84K
2023Q2
853
95.14M
89.25%
-1.89M
2023Q1
864
93.47M
88.04%
+2.38M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Fidelity Management & Research Company LLC
16.49M
14.79%
+257.14K
+1.58%
Mar 31, 2025
The Vanguard Group, Inc.
11.23M
10.07%
-544.61K
-4.63%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
8.78M
7.88%
-135.87K
-1.52%
Mar 31, 2025
Wyss (Hansjorg)
8.14M
7.3%
--
--
Apr 04, 2025
Soleus Capital Management, L.P.
5.52M
4.95%
+2.78M
+101.53%
Mar 31, 2025
Capital World Investors
5.22M
4.68%
+400.00K
+8.31%
Mar 31, 2025
State Street Global Advisors (US)
2.59M
2.32%
-52.73K
-2.00%
Mar 31, 2025
Geode Capital Management, L.L.C.
2.46M
2.21%
+63.41K
+2.64%
Mar 31, 2025
BlackRock Financial Management, Inc.
2.06M
1.85%
+71.86K
+3.61%
Mar 31, 2025
Marshall Wace LLP
1.81M
1.62%
+1.54M
+567.13%
Mar 31, 2025
查看更多
持股ETF
更新时间: 7月6日 周日
更新时间: 7月6日 周日
机构名称
占比
Global X HealthTech ETF
1.92%
SPDR S&P Health Care Equipment ETF
1.85%
ROBO Global Healthcare Technology & Innovation ETF
1.63%
Amplify BlueStar Israel Technology ETF
0.93%
iShares Health Innovation Active ETF
0.53%
VanEck Israel ETF
0.42%
First Trust Small Cap Growth AlphaDEX Fund
0.34%
Global X Aging Population ETF
0.34%
Nuveen ESG Small-Cap ETF
0.25%
ProShares Ultra Nasdaq Biotechnology
0.23%
查看更多
Global X HealthTech ETF
占比1.92%
SPDR S&P Health Care Equipment ETF
占比1.85%
ROBO Global Healthcare Technology & Innovation ETF
占比1.63%
Amplify BlueStar Israel Technology ETF
占比0.93%
iShares Health Innovation Active ETF
占比0.53%
VanEck Israel ETF
占比0.42%
First Trust Small Cap Growth AlphaDEX Fund
占比0.34%
Global X Aging Population ETF
占比0.34%
Nuveen ESG Small-Cap ETF
占比0.25%
ProShares Ultra Nasdaq Biotechnology
占比0.23%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
